| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 03/30/2004 | US6713491 For use as medicine for antagonising the effects of excitatory amino acids upon the nmda receptor complex |
| 03/30/2004 | US6713489 Treatment of atherosclerosis, obesity, diabetes, hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia, hypertriglyceridemia, hypoalphalipoproteinemia, pancreatitis, myocardial infarction, stroke, restenosis, or syndrome x |
| 03/30/2004 | US6713487 Heterocyclic amine derivatives; for treating an inflammatory or immune disease, a cardiovascular disease, or a neurodegenerative condition |
| 03/30/2004 | US6713485 Antiproliferative agents; side effect reduction |
| 03/30/2004 | US6713483 [1,2,3]-triazolo[4,5-d] pyrimidine compounds |
| 03/30/2004 | US6713482 Such as (e)-1-(2-pyridyl)-2-styryl-1h-benzimidazole; antiinflammatory and analgesic agents; prostaglandin inhibitors |
| 03/30/2004 | US6713475 Tricyclic benzodiazepines (cyclic oligopeptides), useful for treatment of hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal failure, stroke or thrombosis |
| 03/30/2004 | US6713472 Thiazine or pyrazine derivatives |
| 03/30/2004 | US6713468 Methods of using thiazolobenzoheterocycles |
| 03/30/2004 | US6713451 Insulin-like growth factor agonist molecules |
| 03/30/2004 | US6713301 Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens |
| 03/30/2004 | US6713268 Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation |
| 03/30/2004 | US6713065 Methods of using hedgehog proteins to modulate hematopoiesis and vascular growth |
| 03/30/2004 | CA2314115C Process for the optical resolution of the racemic 6-(4-amino-phenyl)-5- methyl-pyridazin-3(2h)one |
| 03/30/2004 | CA2291222C Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation |
| 03/30/2004 | CA2262637C Use of hyaluronidase |
| 03/30/2004 | CA2215470C Heterocyclic diaryl compounds, pharmaceutical and cosmetic compositions containing same, and uses thereof |
| 03/30/2004 | CA2133861C Preparation for the treatment of circulatory changes |
| 03/30/2004 | CA2091058C Methylen-oxindole derivatives and process for their preparation |
| 03/30/2004 | CA2079706C Inhibitor of atherosclerotic intimal thickening |
| 03/25/2004 | WO2004025270A2 Methods for measuring rates of reserve cholesterol transport in vivo, as an index of anti-atherogenesis |
| 03/25/2004 | WO2004024921A1 Human antihuman mcp-1 antibody and antibody fragment thereof |
| 03/25/2004 | WO2004024883A2 PAKs AS MODIFIERS OF THE CHK PATHWAY AND METHODS OF USE |
| 03/25/2004 | WO2004024766A1 Kdr peptides and vaccines containing the same |
| 03/25/2004 | WO2004024754A1 Proline ester and preparation containing the same for percutaneous administration |
| 03/25/2004 | WO2004024726A1 N-substituted-1h-indol-5-propionic acid compounds as ppar agonists useful for the treatment of diabetes |
| 03/25/2004 | WO2004024717A1 Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same |
| 03/25/2004 | WO2004024705A1 Five-membered heterocyclic compounds |
| 03/25/2004 | WO2004024701A1 Heterocyclic derivatives |
| 03/25/2004 | WO2004024700A1 Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes |
| 03/25/2004 | WO2004024694A1 4-(substituted aryl)-5-hydroxyisoquinolinone derivative |
| 03/25/2004 | WO2004024679A1 Inhibitors of factor xa and other serine proteases involved in the coagulation cascade |
| 03/25/2004 | WO2004024677A1 N-hydroxyformamidine derivative |
| 03/25/2004 | WO2004024673A1 Amino-propanol derivatives |
| 03/25/2004 | WO2004024158A1 Use of 5-chloro-4-[3-[n-[2-(3,4-dimethoxy-phenyl)-ethyl]-n-methylamino]-propylamino]-3-(2h)-pyridazinone as metabolic modulator |
| 03/25/2004 | WO2004024153A2 Calcium channel blockers |
| 03/25/2004 | WO2004024135A1 Antiarrythmic agent |
| 03/25/2004 | WO2004024129A1 Induced remission therapy |
| 03/25/2004 | WO2004024094A2 Methods and compositons for the use of d-malic acid to decrease serum triglyceride, cholesterol, and lipoprotein levels |
| 03/25/2004 | WO2004024088A2 Design of chemokine analogs for the treatment of human diseases |
| 03/25/2004 | WO2004024086A2 Compounds, compositions and methods |
| 03/25/2004 | WO2004013138A3 Imidazo`1,2-a!pyridines |
| 03/25/2004 | WO2004013134A3 Compounds |
| 03/25/2004 | WO2004004665A3 Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
| 03/25/2004 | WO2004000808A3 N-substituted piperidine derivatives as serotonin receptor agents |
| 03/25/2004 | WO2004000214A3 Use of compounds having an amine nucleus in manufacture of a medicament useful for treating factor viia-associated conditions |
| 03/25/2004 | WO2003104207A3 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia |
| 03/25/2004 | WO2003103675A3 Combination treatments for purinoceptor-related disorders |
| 03/25/2004 | WO2003103603A3 Novel formate salt of o-desmethyl-venlafaxine |
| 03/25/2004 | WO2003092669A3 Method of treating vascular endothelial growth factor mediated vascular disorders using amfenac or nepafenac |
| 03/25/2004 | WO2003092624A3 Use of heat shock proteins to enhance efficacy of antibody therapeutics |
| 03/25/2004 | WO2003087050A3 Novel perindopril salt and pharmaceutical compositions containing same |
| 03/25/2004 | WO2003086326A3 G-type peptides to ameliorate atherosclerosis |
| 03/25/2004 | WO2003086306B1 5ht2c receptor modulators |
| 03/25/2004 | WO2003084941A3 Hydroxamic acid derivatives |
| 03/25/2004 | WO2003084926A3 Polymeric acyl derivatives of indoles |
| 03/25/2004 | WO2003084565A3 Ve-ptp as regulator of ve-cadherin mediated processes or disorders |
| 03/25/2004 | WO2003082271A3 Indole derivatives having anti-angiogenetic activity |
| 03/25/2004 | WO2003080070A3 Combination comprising an hmg-coa reductase inhibittor and an insulin secretor enhancer or an insulin sensitizer |
| 03/25/2004 | WO2003077949A3 Methods of treating diabetes using pde 11a inhibitors |
| 03/25/2004 | WO2003075746A3 Methods for aneurysm repair |
| 03/25/2004 | WO2003075741A9 METHODS OF PREVENTING OR TREATING DISORDERS BY ADMINISTERING AN INTEGRIN αvβ3 ANTAGONIST IN COMBINATION WITH AN HMG-CoA REDUCTASE INHIBITOR OR A BISPHOSPHONATE |
| 03/25/2004 | WO2003072528A3 (substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases |
| 03/25/2004 | WO2003059372A3 Combined use of a glp-1 compound and a modulator of diabetic late complications |
| 03/25/2004 | WO2003059266A3 Post-conditioning for the reduction of ischemic-reperfusion injury in the heart and other organs |
| 03/25/2004 | WO2003054156A3 Novel g proein-coupled receptor, gave7 |
| 03/25/2004 | WO2003048106A3 1,3-diarylprop-2-en-1-ones, compositions containing same and use thereof |
| 03/25/2004 | WO2003043613A3 Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents |
| 03/25/2004 | WO2003040296A3 Men protein, gst2, rab-rp1, csp, f-box protein lilina/fbl7, abc50, coronin, sec61 alpha, or vhappa1-1, or homologous proteins involved in the regulation of energy homeostasis |
| 03/25/2004 | WO2003040134A9 Methods for preparing an estrogenic preparation and isolated estrogenic compounds from a plant and uses thereof |
| 03/25/2004 | WO2003037860A3 Purine analogs having hsp90-inhibiting activity |
| 03/25/2004 | WO2003037361A3 Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis |
| 03/25/2004 | WO2003033680A3 Kinases and phosphatases |
| 03/25/2004 | WO2003020749A3 Ncam binding compounds |
| 03/25/2004 | WO2003020215A3 Methods of treating mycocardial event related coditions with thymosin beta 4 |
| 03/25/2004 | WO2003016351A3 N - cam related compounds modulating cell groth |
| 03/25/2004 | WO2003014731B1 The natural ligand for orphan g protein coupled receptor gpr86 and methods of use |
| 03/25/2004 | WO2003014301A3 Hprp4s as modifiers of the p53 pathway and methods of use |
| 03/25/2004 | WO2003012122A8 Crystallized structure of type iv collagen nc1 domain hexamer |
| 03/25/2004 | WO2002063006A3 Receptors and membrane-associated proteins |
| 03/25/2004 | WO2002044342A3 Hematopoietic cell e-selection/l-selectin ligand polypeptides and methods of use thereof |
| 03/25/2004 | WO2002039998A3 Methods and compositions for regulating memory consolidation |
| 03/25/2004 | WO2002017899A3 Regulation of angiogenesis via modulation of edg receptor mediated signal transduction comprising sphingosine-1-phosphate administration |
| 03/25/2004 | WO2002002095B1 Compositions for treating bacterial infections containing oxazolidinone compound, sulbactam and an ampicillin |
| 03/25/2004 | US20040059144 Aspirin-triggered lipid mediators |
| 03/25/2004 | US20040059132 Reacting an indolin-2-one derivative with substituted benzyl halide to form substituted N-benzyl indolin-2-one derivatives have an affinity for oxytocin receptors |
| 03/25/2004 | US20040059130 Benz(f)indole compounds useful for Inflammatory Diseases |
| 03/25/2004 | US20040059113 Such as 3-(1-(2-hydroxyethyl)-1H-indol-3-yl)-4-(1-(3-pyridinyl)-1H-indol-3-yl)-1H -pyrrole-2,5-dione |
| 03/25/2004 | US20040059110 Such as N,N'-bis(2-hydroxybenzyl)-L-cystine |
| 03/25/2004 | US20040059107 Which has superoxide acitivity, catalase activity, and/or peroxidase activity; for treating cell or tissue damage; pharmaceutical formulations, improved cell and organ culture media, cryopreservation media, antiaging, chemoprotective and radioprotective uses |
| 03/25/2004 | US20040059089 Comprises receptor protein for controlling gene expression in transgenic cells; for diagnosis, prevention and treatment of heart, tumor and urogenital disorders |
| 03/25/2004 | US20040059004 10-aryl-11h-benzo[b]fluorene derivatives and analogs for medicinal use |
| 03/25/2004 | US20040058987 Hypotensive agents; oxidation resistance, nitrogen scavenger; anticancer agents; antiischemic agents |
| 03/25/2004 | US20040058986 Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease |
| 03/25/2004 | US20040058980 Useful aroyl pyrrole heteroaryl methanones and methanols |
| 03/25/2004 | US20040058972 Therapy for neovascularization; antitumor agents; vision defects; antidiabetic agents; antiarthritic agents |
| 03/25/2004 | US20040058967 Crystalline organic acid salt of amlodipine |
| 03/25/2004 | US20040058965 Alkanoic acid derivatives process for their production and use thereof |
| 03/25/2004 | US20040058964 Antiinflammatory agents; antiarthritic agents; antihistamines; sepsis shock; antidiabetic agents; bone disorders |
| 03/25/2004 | US20040058963 Cardiovascular disorders; hypotensive agents; antiallergens; antihistamines; antiarthritic agents; skin disorders |